HHorinouchi· @HHorinouchi · X·· 2 天前评分60
正文 · 原文
🆙#ESMO26 Proffered Paper: #LCSM Non-Mets 🔥PEARLS/KEYNOTE-091: Final Analysis of Adjuvant Pembrolizumab (Pembro) in Resected Early-Stage Non–Small-Cell Lung Cancer (NSCLC): Phase 3 Study 🎙️ @drMaryOBr 🔢2511O 🎯Consistent DFS Benefit (HR 0.85, 58.7 vs 43.3mo; n=1177) 🎯6-Yr OS 68.5% vs 66.4% (HR 0.98, NS) 🎯Favorable LCSS Trend (HR 0.81) ☑️NCT02504372 🔗 https://t.co/grEfaUchKN @OncoAlert @Larvol @myESMO @IASLC
热度 4 · 3 赞 · 0 回复 · 1 转发
会议摘要
NCT02504372NCT02504372按 - **标题 / Title：** Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) 对上
- **标题 / Title：** Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)读摘要原文 →来源：HHorinouchi · x.com